Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 20

Outcome	Group	Value	Spread	Units
Time to Flare by Week 26	Mavrilimumab	NA	95% Confidence Interval NA to NA	weeks
Time to Flare by Week 26	Placebo	25.1	95% Confidence Interval 16.0 to NA	weeks
Sustained Remission Rate at Week 26	Mavrilimumab	83.2	95% Confidence Interval 67.9 to 91.6	percentage of participants
Sustained Remission Rate at Week 26	Placebo	49.9	95% Confidence Interval 29.6 to 67.3	percentage of participants
Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26	Mavrilimumab	26.1	95% Confidence Interval 16.1 to NA	weeks
Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26	Placebo	12.1	95% Confidence Interval 8.1 to 16.6	weeks
Time to Elevated C-Reactive Protein (CRP) by Week 26	Mavrilimumab	NA	95% Confidence Interval 8.1 to NA	weeks
Time to Elevated C-Reactive Protein (CRP) by Week 26	Placebo	12.3	95% Confidence Interval 3.3 to 24.1	weeks
Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26	Mavrilimumab	NA	95% Confidence Interval NA to NA	weeks
Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26	Placebo	25.1	95% Confidence Interval 15.1 to NA	weeks
Cumulative Corticosteroid Dose at Week 26	Mavrilimumab	2074.15	Standard Deviation 708.433	mg
Cumulative Corticosteroid Dose at Week 26	Placebo	2402.98	Standard Deviation 1014.446	mg
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR	Mavrilimumab	45.2	95% Confidence Interval 29.8 to 61.3	percentage of participants
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR	Placebo	14.3	95% Confidence Interval 4.0 to 32.7	percentage of participants
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level	Mavrilimumab	23.8	95% Confidence Interval 12.1 to 39.5	percentage of participants
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level	Placebo	14.3	95% Confidence Interval 4.0 to 32.7	percentage of participants
Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26	Mavrilimumab	71.4	95% Confidence Interval 55.4 to 84.3	percentage of participants
Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26	Placebo	32.1	95% Confidence Interval 15.9 to 52.4	percentage of participants
Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period	Mavrilimumab	2464.93	Standard Deviation 1106.636	mg
Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period	Placebo	2845.45	Standard Deviation 1320.115	mg

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03827018/results

API reference For AI assistants